You’re using a public version of DrugPatentWatch with 5 free searches available | Register to unlock more free searches. CREATE FREE ACCOUNT

Last Updated: March 28, 2024

Claims for Patent: 6,913,744


✉ Email this page to a colleague

« Back to Dashboard


Summary for Patent: 6,913,744
Title: Method and composition for treating prostate cancer
Abstract:A method of treating prostate cancer in a living mammal includes local administration of a composition that includes a therapeutically effective concentration of collagenase. In one embodiment, a method of treating prostate cancer in a living mammal includes local administration of a composition that includes a therapeutically effective concentration of collagenase and at least one of a glycosidase, a protease, a nuclease, a lipase, an esterase, a plasminogen activator, a streptokinase, and combinations thereof. Preferably a glycosidase, such as, for example, hyaluronidase, is administered. Compositions used in methods for treating prostate cancer can also include or be administered with calcium ions, a nonionic surfactant, such as, for example, Triton.RTM. X-100, and an antibiotic, such as, for example, gentamicin. Another method of treating prostate cancer in a living mammal includes activating PSA in vivo by, for example, locally administering calcium ions.
Inventor(s): Gokcen; Muharrem (Minneapolis, MN)
Assignee: Immunolytics Inc. (Minneapolis, MN)
Application Number:10/055,063
Patent Claims:1. A method of degrading a prostate tumor in a mammal comprising local administration to the prostate of a composition comprising therapeutically effective concentrations of collagenase, hyaluronidase, and calcium ions.

2. The method of claim 1, wherein the composition comprises about 1 mM to about 50 mM calcium ions.

3. The method of claim 1, wherein the calcium ions comprise a calcium salt.

4. The method of claim 3, wherein the calcium salt comprises calcium chloride.

5. The method of claim 1, wherein the composition comprises about 1 mM to about 50 mM calcium ions, about 250 to about 250,000 U/ml collagenase and about 160 to about 160,000 U/ml hyaluronidase.

6. The method of claim 1, wherein the composition further comprises an effective concentration of a nonionic surfactant.

7. The method of claim 6, wherein the nonionic surfactant comprises octylphenoxypolyethoxyethanol.

8. The method of claim 1, wherein the composition further comprises an effective concentration of an antibiotic.

9. The method of claim 8, wherein the antibiotic comprises gentamicin sulfate.

10. The method of claim 1, wherein local administration comprises intraprostatic injection.

11. The method of claim 10, wherein intraprostatic injection comprises intralesional injection, transurethral injection, transrectal injection, or transperineal injection.

12. The method of claim 10, comprising administering a single injection of about 1 to 50 ml.

13. The method of claim 10, comprising administering a single injection of about 1 to 5 ml.

14. The method of claim 1, wherein local administration comprises administering a depot formulation.

15. The method of claim 1, wherein local administration comprises administering a slow release implant, a microencapsulated composition, a conjugate with a biodegradable polymer, or a conjugate with a prostate-specific immunoglobulin.

16. A method of degrading a prostate tumor in a mammal comprising local administration to the prostate of a sterile pyrogen-free solution comprising effective concentrations of calcium ions, collagenase, hyaluronidase, a nonionic surfactant, an antibiotic, and a pharmaceutically acceptable aqueous carrier having a physiologic pH; wherein the solution is suitable for administration to living mammals at single or multiple dosages of about 1 to 50 ml via intraprostatic injection; and wherein administration of said solution causes the necrosis, liquification, and regression of said tumor.

17. The method of claim 16, wherein collagenase is provided at a concentration of about 2,500 to 25,000 U/ml.

18. The method of claim 16, wherein hyaluronidase is provided at a concentration of about 1,600 to 16,000 U/ml.

19. The method of claim 16, wherein the nonionic surfactant comprises octylphenoxypolyethoxyethanol.

20. The method of claim 16, wherein the antibiotic comprises gentamicin.

21. The method of claim 16, wherein the intraprostatic injection comprises intralesional injection, transurethral injection, transrectal injection, or transperineal injection.

22. The method of claim 16, comprising administering a single injection of about 1 to 20 ml.

Details for Patent 6,913,744

Applicant Tradename Biologic Ingredient Dosage Form BLA Approval Date Patent No. Expiredate
Bausch & Lomb Incorporated VITRASE hyaluronidase Injection 021640 05/05/2004 ⤷  Try a Trial 2019-10-28
Bausch & Lomb Incorporated VITRASE hyaluronidase Injection 021640 12/02/2004 ⤷  Try a Trial 2019-10-28
Amphastar Pharmaceuticals, Inc. AMPHADASE hyaluronidase Injection 021665 10/26/2004 ⤷  Try a Trial 2019-10-28
Akorn, Inc. HYDASE hyaluronidase Injection 021716 10/25/2005 ⤷  Try a Trial 2019-10-28
Smith & Nephew, Inc. SANTYL collagenase Ointment 101995 06/04/1965 ⤷  Try a Trial 2019-10-28
>Applicant >Tradename >Biologic Ingredient >Dosage Form >BLA >Approval Date >Patent No. >Expiredate

Make Better Decisions: Try a trial or see plans & pricing

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.